Soluble urokinase plasminogen activator receptor : A risk factor for carotid plaque, stroke, and coronary artery disease

Stroke

Volumn 45, Issue 1, 2014, Pages 18-23

  Persson, Margaretha ^a,b   Östling, Gerd ^a,b   Smith, Gustav ^b   Hamrefors, Viktor ^b   Melander, Olle ^a,b   Hedblad, Bo ^b   Engström, Gunnar ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Carotid artery plaque; Coronary artery disease

Indexed keywords

EID: 84893665922     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.003305     Document Type: Article

References (35)

1. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol. 2006;4:101-116.
2. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2012;222:8-14.
3. Waltz DA, Fujita RM, Yang X, Natkin L, Zhuo S, Gerard CJ, et al. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol. 2000;22:316-322.
4. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009;27:157-172.
5. Svensson PA, Olson FJ, Hägg DA, Ryndel M, Wiklund O, Karlström L, et al. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. Int J Mol Med. 2008;22:459-464.
6. Kienast J, Padró T, Steins M, Li CX, Schmid KW, Hammel D, et al. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost. 1998;79:579-586.
7. Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;96:4091-4095.
8. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296-308.
9. Persson M, Engström G, Björkbacka H, Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Atherosclerosis. 2012;220:502-505.
10. Edsfeldt A, Nitulescu M, Grufman H, Grönberg C, Persson A, Nilsson M, et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke. 2012;43:3305-3312.
11. Olson FJ, Thurison T, Ryndel M, Høyer-Hansen G, Fagerberg B. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem. 2010;43:124-130.
12. Berglund G, Elmstähl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med. 1993;233:45-51.
13. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intimamedia thickness. J Intern Med. 2005;257:430-437.
14. Wendelhag I, Liang Q, Gustavsson T, Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke. 1997;28:2195-2200.
15. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis. 2005;179:325-331.
16. Persson J. Ultrasound and Atherosclerosis, Evaluation of Methods, Risk Factors and Intevention [thesis]. Malmö, Sweden: Department of Medicine, Lund University; 1997.
17. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem. 2006;52:1284-1293.
18. Hammar N, Alfredsson L, Rosén M, Spetz CL, Kahan T, Ysberg AS. A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J Epidemiol. 2001;30(suppl 1):S30-S34.
19. Khan FA, Zia E, Janzon L, Engstrom G. Incidence of stroke and stroke subtypes in Malmö, Sweden, 1990-2000: marked differences between groups defined by birth country. Stroke. 2004;35:2054-2058.
20. Koul S, Smith JG, Scherstén F, James S, Lagerqvist B, Erlinge D. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J. 2011;32:2989-2997.
21. Sehestedt T, Lyngbak S, Eugen-Olsen J, Jeppesen J, Andersen O, Hansen TW, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis. 2011;216:237-243.
22. Lyngbak S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol. 2013;167:2904-2911.
23. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-943.
24. Steins MB, Padró T, Schwaenen C, Ruiz S, Mesters RM, Berdel WE, et al. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis. 2004;15:383-391.
25. Furlan F, Orlando S, Laudanna C, Resnati M, Basso V, Blasi F, et al. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci. 2004;117(pt 14):2909-2916.
26. Park YJ, Liu G, Tsuruta Y, Lorne E, Abraham E. Participation of the urokinase receptor in neutrophil efferocytosis. Blood. 2009;114:860-870.
27. Wiersinga WJ, Kager LM, Hovius JW, van der Windt GJ, de Vos AF, Meijers JC, et al. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol. 2010;184:3079-3086.
28. Backes Y, van der Sluijs KF, Tuip de Boer AM, Hofstra JJ, Vlaar AP, Determann RM, et al. Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study. Crit Care. 2011;15:R270.
29. Persson J, Stavenow L, Wikstrand J, Israelsson B, Formgren J, Berglund G. Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb. 1992;12:261-266.
30. The National Board of Health and Welfare. Evaluation of Quality of Diagnosis of Acute Myocardial Infarction, Inpatient Register 1997 and 1995. Stockholm, Sweden: Socialstyrelsen; 2000 (in Swedish).
31. Engström G, Jerntorp I, Pessah-Rasmussen H, Hedblad B, Berglund G, Janzon L. Geographic distribution of stroke incidence within an urban population: relations to socioeconomic circumstances and prevalence of cardiovascular risk factors. Stroke. 2001;32:1098-1103.
32. Lyngbak S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2013;167:781-785.
33. Riisbro R, Christensen IJ, Høgdall C, Brünner N, Høgdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers. 2001;16:233-239.
34. Li R, Duncan BB, Metcalf PA, Crouse JR III, Sharrett AR, Tyroler HA, et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994;25:2377-2383.
35. Johnsen SH; The Tromso Study. Ultrasound imaging of carotid atherosclerosis in a normal population. Norsk Epidemiologi. 2009;19:17-28.